Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: A double-blind placebo-controlled study

Psychopharmacology

Volumn 192, Issue 3, 2007, Pages 441-448

  Poyurovsky, Michael ^a,b   Fuchs, Camil ^c,e   Pashinian, Artashez ^a   Levi, Aya ^a   Faragian, Sarit ^a   Maayan, Rachel ^d   Gil Ad, Irit ^d  

^a Technion Medical School   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d GEHA MENTAL HEALTH CENTER   (Israel)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Olanzapine; Reboxetine; Second generation antipsychotics; Weight gain

Indexed keywords

BIPERIDEN; DIAZEPAM; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; TRIHEXYPHENIDYL;

ADULT; AGITATION; APPETITE DISORDER; ARTICLE; BEHAVIOR; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIPSYCHOTIC AGENTS; APPETITE; BENZODIAZEPINES; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 34247898945     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0731-1     Document Type: Article

References (26)

1. Andreasen NC (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa City
2. Andreasen NC (1984) Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City
3. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ (2005) Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5(1):3
4. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
5. Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L (2004) Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37:206-210
6. Bishop JR, Ellingrod VL, Moline J, Miller D (2006) Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 12:BR47-BR50 (Epub 2006 Jan 26)
7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122
8. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 29:607-614
9. Elman I, Borsook D, Lukas SE (2006) Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31:2091-2120
10. First MB, Spitzer RL, Gibbon M (1995) Structured clinical interview for DSM-IV Axis I disorders, Patient Edition (SCID-I/P, version 2.0). Biometric Research, New York State Psychiatric Institute, New York, NY
11. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057
12. Guy W (1976) ECDE assessment manual for psychopharmacology. Revised DHEW Pub (ADM). National Institute of Mental Health, Rockville, MD
13. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
14. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC (2005) A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162:954-962
15. Kanders BS, Forse RA, Blackburn GL (1991) Methods in obesity. In: Rakel RE (ed) Conn's current therapy. WB Saunders, Philadelphia, pp 524-532
16. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92-100
17. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255-258
18. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
19. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C (2006) Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry 67:547-553
20. Newcomer JW, Haupt DW (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 51:480-491
21. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC, Lim SW, Paik JW, Lee HJ (2006) Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 141:394-397
22. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A (2003) Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160:297-302
23. Schatzberg AF (2000) Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61(Suppl 10):31-38
24. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(Suppl):11-19
25. Spina E, Scordo MG, D'Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517-538
26. Ste Marie L, Luquet S, Curtis W, Palmiter RD (2005) Norepinephrine-and epinephrine-deficient mice gain weight normally on a high-fat diet. Obes Res 13(9):1518-1522